Predictive Genetic Test For Bowel Cancer Treatment Is Introduced In The UK

Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment in the UK. Under the terms of the agreement, leading diagnostics company Lab21 will provide a screening test to indicate which patients are likely to benefit from Amgen’s new drug for advanced bowel cancer Vectibix® (panitumumab).

More: continued here

Filed under: Colorectal Cancer on April 2nd, 2008